Merck & Co. Stock - Sunday background on pipeline and cancer focus

Merck & Co. stock gets a Sunday background check: how the US pharma group earns much of its money with cancer blockbuster Keytruda, what its broader pipeline looks like, and where the New York-listed shares currently trade.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 11:00 UTC. Details in the imprint.

Merck & Co. (US58933Y1055) is one of the largest US pharmaceutical companies by market value. With no fresh market-moving headlines from Reuters or company releases over the weekend, the stock lends itself to a Sunday background look at its cancer-driven business model.

How Merck & Co. earns its money

Merck & Co. generates most of its revenue from prescription medicines, with a strong concentration in oncology and vaccines. The best-known product is the immuno-oncology drug Keytruda, which is approved across multiple cancer types worldwide.

According to the company’s latest available annual figures, oncology products, led by Keytruda, now account for well over one third of group sales. Vaccines, including the HPV vaccine Gardasil/Gardasil 9, form the second major pillar of the portfolio.

Keytruda’s central role in earnings

Keytruda has become one of the world’s top-selling prescription medicines, with annual sales already in the tens of billions of dollars. The drug is used in indications such as non-small cell lung cancer, melanoma and several others.

Analysts point out that Merck & Co.’s earnings sensitivity to Keytruda is high, as the product contributes a substantial share of operating profit. That makes the lifecycle of the drug, and efforts to broaden its label, strategically important for the stock.

What the Sunday background shows

From a Sunday perspective, the Merck & Co. story is dominated by two themes: how long Keytruda can sustain its current growth and how effectively the company builds follow-on assets. Both factors will influence longer-term valuation.

Patent protection for Keytruda is expected to phase down in the early 2030s in major markets, according to company guidance. Until then, the group is trying to maximize its reach across indications and combinations, while ramping other oncology and vaccine franchises.

Management, strategy and pipeline

Merck & Co. is led by CEO Robert Davis, who took over the role in 2021 after previously serving as CFO. Under his leadership, the company has focused on oncology, vaccines and cardiometabolic diseases as priority therapeutic areas.

Strategically, Merck & Co. tends to complement internal research with bolt-on acquisitions and licensing deals. The goal is to secure additional late-stage assets that can reduce future reliance on Keytruda once generics and biosimilars emerge.

Position in the global pharma sector

With a market capitalization in the area of several hundred billion dollars, Merck & Co. ranks among the largest constituents of the Standard & Poor’s 500 index healthcare cohort. The stock is widely held in global pharmaceutical and dividend-focused funds.

Compared with peers, the group’s earnings profile is more concentrated, given the outsized contribution from a single oncology franchise. However, the vaccine business and growing cardiometabolic pipeline provide some diversification relative to pure-play oncology names.

The product behind the stock

One emblematic product behind Merck & Co. stock is the cancer therapy Keytruda (pembrolizumab), a humanized monoclonal antibody that blocks the PD-1 pathway. It helps the immune system detect and fight tumor cells across multiple advanced and metastatic cancer types.

Where the stock trades today

Merck & Co. shares (US58933Y1055) last closed on the New York Stock Exchange at $113.87 on 06/18/2026, 16:00 ET.

Key facts on Merck & Co. stock

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• WKN: A3CSGV
• Ticker: MRK
• Venue: NYSE
• Price (as of 06/18/2026, 16:00 ET): 113.87 USD
• Market cap: 281.24 billion USD (as of 06/18/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.